Synthesis and evaluation as PDE4 inhibitors of pyrimidine‐2,4‐dione derivatives

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Drug Development Research

• Publication date

  2011-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/ddr.20395
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• A Comparison of Phenylboronic Acid and Phenyltrimethyltin in the Palladium‐Catalyzed Arylation of 1,5‐Dialkylimidazoles.

  2010cited by this paper
• SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.

  2007cited by this paper
• Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors

  2007cited by this paper
• Synthesis and in vitro antiplatelet activity of new 4-(1-piperazinyl)coumarin derivatives. Human platelet phosphodiesterase 3 inhibitory properties of the two most effective compounds described and molecular modeling study on their interactions with phosphodiesterase 3A catalytic site.

  2007cited by this paper
• Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.

  2006cited by this paper
• Straightforward Pyrimidine Ring Construction: A Versatile Tool for the Synthesis of Nucleobase and Nucleoside Analogues

  2006cited by this paper
• Local anti-inflammatory effect and behavioral studies on new PDE4 inhibitors.

  2006cited by this paper
• The Potential Role of Roflumilast: The New Phosphodiesterase-4 Inhibitor

  2006cited by this paper
• Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.

  2005cited by this paper
• Gateways to clinical trials.

  2005cited by this paper
• Keynote review: phosphodiesterase-4 as a therapeutic target.

  2005cited by this paper
• Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells

  2005cited by this paper
• Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4

  2004cited by this paper
• Inhibition of the Phosphodiesterase 4 (PDE4) Enzyme Reverses Memory Deficits Produced by Infusion of the MEK Inhibitor U0126 into the CA1 Subregion of the Rat Hippocampus

  2004cited by this paper
• The potential of PDE4 inhibitors in respiratory disease.

  2004cited by this paper
• Polymer-supported copper complex for C-N and C-O cross-coupling reactions with aryl boronic acids.

  2004influential reference
• Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4).

  2004cited by this paper
• Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa.

  2004cited by this paper
• Ligand- and base-free copper(II)-catalyzed C-N bond formation: cross-coupling reactions of organoboron compounds with aliphatic amines and anilines.

  2003cited by this paper
• Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site

  2002cited by this paper
• Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells.

  2002cited by this paper
• Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.

  2001cited by this paper
• Phosphodiesterase 4 Inhibitors Prevent Cytokine Secretion by T Lymphocytes by Inhibiting Nuclear Factor-κB and Nuclear Factor of Activated T Cells Activation

  2001cited by this paper
• PDE4 cAMP-specific phosphodiesterases.

  2001cited by this paper
• Aza analogues of thalidomide: synthesis and evaluation as inhibitors of tumor necrosis factor-alpha production in vitro.

  2001cited by this paper
• Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies.

  2000cited by this paper
• Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells.

  2000cited by this paper
• 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.

  1998cited by this paper
• Heterocyclic-fused 3(2H)-pyridazinones as potent and selective PDE IV inhibitors: Further structure-activity relationships and molecular modelling studies

  1998cited by this paper
• SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions.

  1998cited by this paper
• The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions.

  1998cited by this paper
• Thalidomide analogs and PDE4 inhibition.

  1998cited by this paper
• OPC-6535, a superoxide anion production inhibitor, attenuates acute lung injury.

  1997cited by this paper
• Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases.

  1997cited by this paper
• Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.

  1997cited by this paper
• 2 – Analysis of PDE Isoenzyme Profiles in Cells and Tissues by Pharmacological Methods

  1996cited by this paper
• Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.

  1995cited by this paper
• Section Review: Cardiovascular & Renal: Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiovascular diseases

  1995cited by this paper
• A comparison of phenylboronic acid and phenyltrimethyltin in the palladium‐catalyzed arylation of 1,5‐dialkylimidazoles

  1994cited by this paper
• Selective Oxidative Halogenation of Uracils.

  1994cited by this paper
• Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate.

  1993cited by this paper
• Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity.

  1992cited by this paper
• Improved One-Step Procedure for the Preparation of 1-Substituted and 1,3-Disubstituted Uracils and 2-Thiouracils

  1986cited by this paper
• Stereospecific binding of the antidepressant rolipram to brain protein structures.

  1986cited by this paper
• TVX 2706 — a new phosphodiesterase inhibitor with antiinflammatory action Biochemical characterization

  1984cited by this paper
• Purification and characterization of a human platelet cyclic nucleotide phosphodiesterase.

  1984cited by this paper
• A sensitive assay employing a solid-phase metal chelator to estimate rates of iron accumulation by ferritin.

  1982cited by this paper
• Ligand: a versatile computerized approach for characterization of ligand-binding systems.

  1980cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper

• PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes

  2023influential citation
• New quinoline-based PDE4 inhibitors through GSK-256066 fragment-based elaboration

  2023cites this paper
• Research developments in the syntheses, anti-inflammatory activities and structure–activity relationships of pyrimidines

  2021cites this paper